{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:22Z","timestamp":1792172362120,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,6]]},"DOI":"10.7759\/cureus.55666","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T19:55:20Z","timestamp":1709754920000},"source":"Crossref","is-referenced-by-count":8,"title":["Acute Non-infectious Cystitis Secondary to Immune-Related Adverse Events in a Patient Receiving Pembrolizumab for Treatment of Non-small Cell Lung Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Leena","family":"Alhusari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemnasom","family":"Nwanwene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Shenouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das S","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019, 7:306. 10.1186\/s40425-019-0805-8","journal-title":"J Immunother Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1801663","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Kumar B","year":"2018","unstructured":"Kumar B, Ballas Z. Adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:1164. 10.1056\/NEJMc1801663","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102350","article-title":"Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC","volume":"104","author":"Friedlaender A","year":"2022","unstructured":"Friedlaender A, Naidoo J, Banna GL, Metro G, Forde P, Addeo A. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treat Rev. 2022, 104:102350. 10.1016\/j.ctrv.2022.102350","journal-title":"Cancer Treat Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber JS","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al.. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017, 35:785-92. 10.1200\/JCO.2015.66.1389","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12211","article-title":"Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma","volume":"3","author":"Ueki Y","year":"2020","unstructured":"Ueki Y, Matsuki M, Kubo T, et al.. Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma. IJU Case Rep. 2020, 3:266-9. 10.1002\/iju5.12211","journal-title":"IJU Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2017.12.006","article-title":"Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor","volume":"17","author":"Shimatani K","year":"2018","unstructured":"Shimatani K, Yoshimoto T, Doi Y, Sonoda T, Yamamoto S, Kanematsu A. Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor. Urol Case Rep. 2018, 17:97-9. 10.1016\/j.eucr.2017.12.006","journal-title":"Urol Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0298-6","article-title":"A case of cystitis after administration of nivolumab","volume":"6","author":"Ozaki K","year":"2017","unstructured":"Ozaki K, Takahashi H, Murakami Y, Kiyoku H, Kanayama H. A case of cystitis after administration of nivolumab. Int Cancer Conf J. 2017, 6:164-6. 10.1007\/s13691-017-0298-6","journal-title":"Int Cancer Conf J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757069","article-title":"Case report: A case of sintilimab-induced cystitis\/ureteritis and review of sintilimab-related adverse events","volume":"11","author":"Tu L","year":"2021","unstructured":"Tu L, Ye Y, Tang X, Liang Z, You Q, Zhou J, Pan Z. Case report: A case of sintilimab-induced cystitis\/ureteritis and review of sintilimab-related adverse events. Front Oncol. 2021, 11:757069. 10.3389\/fonc.2021.757069","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja L","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017, 28:2377-85. 10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"ref10","unstructured":"National Cancer Institute (US). Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE). (2021). Accessed. March 5, 2024: http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan M","year":"2021","unstructured":"Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021, 184:1575-88. 10.1016\/j.cell.2021.02.011","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar V","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB.  Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017, 8:49. 10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/232236-acute-non-infectious-cystitis-secondary-to-immune-related-adverse-events-in-a-patient-receiving-pembrolizumab-for-treatment-of-non-small-cell-lung-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T19:55:24Z","timestamp":1709754924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/232236-acute-non-infectious-cystitis-secondary-to-immune-related-adverse-events-in-a-patient-receiving-pembrolizumab-for-treatment-of-non-small-cell-lung-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.55666","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}